Micafungin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Candidiasis, Systemic
Conditions
Candidiasis, Systemic, Candida Meningitis
Trial Timeline
May 30, 2015 → Apr 10, 2018
NCT ID
NCT03421002About Micafungin
Micafungin is a phase 2 stage product being developed by Astellas Pharma for Candidiasis, Systemic. The current trial status is completed. This product is registered under clinical trial identifier NCT03421002. Target conditions include Candidiasis, Systemic, Candida Meningitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03174457 | Pre-clinical | Completed |
| NCT03102658 | Approved | Completed |
| NCT02440178 | Phase 2 | Completed |
| NCT03421002 | Phase 2 | Completed |
| NCT02678598 | Pre-clinical | Completed |
| NCT02127788 | Pre-clinical | Completed |
| NCT02646800 | Approved | Terminated |
| NCT02646774 | Approved | Terminated |
| NCT02057289 | Phase 1 | Terminated |
| NCT01982071 | Approved | Terminated |
| NCT01135589 | Approved | UNKNOWN |
| NCT00606268 | Phase 1 | Completed |
| NCT00608335 | Phase 1 | Completed |
| NCT00818584 | Phase 1 | Completed |
| NCT00842504 | Phase 1 | Completed |
Competing Products
20 competing products in Candidiasis, Systemic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| Isavuconazole + Caspofungin + Voriconazole | Astellas Pharma | Phase 3 | 77 |
| Micafungin + fluconazole | Astellas Pharma | Phase 3 | 77 |
| Micafungin (Mycamine) | Astellas Pharma | Phase 1 | 33 |
| Fluconazole + Micafungin | Astellas Pharma | Approved | 85 |
| Micafungin + Caspofungin | Astellas Pharma | Phase 3 | 77 |
| Micafungin + Fluconazole | Astellas Pharma | Phase 3 | 77 |
| micafungin + caspofungin | Astellas Pharma | Phase 3 | 77 |
| micafungin + amphotericin B deoxycholate | Astellas Pharma | Phase 3 | 77 |
| FK463 | Astellas Pharma | Phase 2 | 52 |
| Micafungin + Liposomal Amphotericin B | Astellas Pharma | Phase 3 | 77 |
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| L-743,872 | Merck | Pre-clinical | 23 |
| Caspofungin | Merck | Phase 2 | 52 |
| L-743,872 | Merck | Phase 2 | 52 |
| Caspofungin + Amphotericin B Deoxycholate | Merck | Phase 2 | 52 |
| Caspofungin acetate + Placebo | Merck | Phase 2 | 52 |
| Caspofungin + Normal Saline | Merck | Approved | 85 |
| caspofungin acetate | Merck | Phase 3 | 77 |